Pharmacokinetic, Safety, Tolerability, Immunogenicity, and Pharmacodynamic Study of SB12 in Healthy Subjects
Status:
Completed
Trial end date:
2019-04-08
Target enrollment:
Participant gender:
Summary
This study is to evaluate PK, safety, tolerability, immunogenicity, and PD profiles of SB12,
EU sourced Soliris, and US sourced Soliris in healthy subjects.